Ab-Externo Xen Glaucoma Microstent Implantation In The Treatment Of Glaucoma - A 1-Year Retrospective Observational Study
Published 2024 - 42nd Congress of the ESCRS
Reference: PO1053 | Type: Poster | DOI: 10.82333/85sy-zb36
Authors: Paulina Langosz* 1 , Wojciech Maruszczyk 1 , Krzysztof Eder 2 , Agnieszka Mrozek 1 , Mateusz Porwolik 2 , Dominik Dygas 1 , Julia Janiszewska-Salamon 2 , Dorota Wygledowska-Promienska 2 , Adrian Smedowski 3
1Department of Ophthalmology,Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice,Katowice,Poland, 2Department of Ophthalmology,Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice,Katowice,Poland;Department of Ophthalmology,Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice,Katowice,Poland, 3Department of Ophthalmology,Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice,Katowice,Poland;Department of Ophthalmology,Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice,Katowice,Poland;Glaucotech sp. z o.o.,Katowice,Poland
Purpose
The purpose of our work was to evaluate the efficacy and complications of ab-externo XEN gel microstent (XEN, Aquesys, Inc.) implantations as a treatment modality for various types of glaucoma.
Setting
We analyzed the clinical history of 28 eyes that underwent a total of 32 XEN stent implantations at the University Clinical Center of the Medical University of Silesia over the past year as a treatment for diverse types of glaucoma with SOAG as the leading type. The mean age of the population was 65 (IQR 47-71), the mean length of glaucoma pharmacotherapy before the implantation was 6.5 (2.0-12.5) years. 20 eyes were pseudophakic and 22 underwent a prior invasive treatment.
Methods
In this retrospective observational study the abovementioned group of eyes has been observed for 9±3 months especially in terms of post-implantation BCVA and IOP profile. The latter have been measured and analyzed by means of the Goldmann applanation tonometry and corrected for CCT. Further, surgical complications, need for further glaucoma pharmacotherapy as well as the necessity of repeated surgical interventions during the observation period have been analyzed. Subjective ailments reported by the patients in the period of observation have been numbered.
Results
We have observed an IOP drop from 30.0 (22.5-39.5) on admission to 8.0 (8.0-10.0) on discharge, with further values of 11.0 (7.0-15.0); 14.0 (11.5-19.0); 17.0 (14.0-20.0); 18.0 (14.0-19.0) at the 1-week, 1, 3, and 6-month controls respectively. Number of glaucoma topical medications dropped from 3 (3-4) pre-surgery to 0 (0-0) immediately post-op. BCVA pre-op was 0.15 (0.05-0.61) logMAR and improved to 0.1 (0.00-0.52) at the 6-month control. 14 eyes required a surgical revision and 5 of all the eyes have been further qualified to repeated surgical treatment in different modality. The only relevant surgery complication has been recurrence of elevated IOP and none of the eyes underwent an implant extrusion within the observation period.
Conclusions
The ab externo method for XEN microstent implantation has been proved to be an effective glaucoma treatment modality, drastically decreasing the necessity for both further pharmacotherapy and/or follow-up surgical procedures. The subjective ailments reported by patients have been found to be at a acceptable level with the majority of the population described having experienced a considerable improvement in the reported quality of life.